Payment overview · 2025
General Payments
$1,004.52
66 reported records · 19 companies
Healthcare provider profile · identity verified
Bryon D Hirschman, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORFOLK, NE · NPI 1194739912
Verified facts
What the public records show
CMS Open Payments records show Bryon D Hirschman, MD received $1,004.52 in general payments during 2025 across 66 reported records.
ABBVIE INC. accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Fanapt, Linzess, Mounjaro, Ozempic, Rybelsus, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 806 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xifaxan by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $254.26 | 25.3% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $137.69 | 13.7% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $90.79 | 9.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.40 | 8.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.44 | 7.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.68 | 5.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $45.54 | 4.5% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.07 | 3.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $33.97 | 3.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.08 | 3.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.79 | 3.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.99 | 2.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.51 | 1.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.44 | 1.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.91 | 1.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $15.66 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.36 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.98 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.96 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,004.52 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $201.51 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $155.31 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $110.30 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $77.56 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $77.56 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $77.56 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.13 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $60.13 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $55.46 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.68 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $45.54 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $45.54 | 3 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $45.54 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $36.59 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $34.07 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $34.07 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.08 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.94 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.94 | 2 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $28.97 | 2 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $28.97 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.73 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.16 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $3.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FANAPT fanapt |
2025 | Fanapt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 90 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
90 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
135 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
301 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
806 | 107 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
41 | 39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1719 | 336 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1608 | 347 |
| Losartan Potassium | Losartan Potassium | 1278 | 281 |
| Potassium Chloride | Potassium Chloride | 1085 | 230 |
| Omeprazole | Omeprazole | 966 | 212 |
| Pantoprazole Sodium | Pantoprazole Sodium | 861 | 191 |
| Eliquis | Apixaban | 806 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 793 | 188 |
| Furosemide | Furosemide | 781 | 189 |
| Gabapentin | Gabapentin | 767 | 147 |
| Lisinopril | Lisinopril | 712 | 163 |
| Metoprolol Tartrate | Metoprolol Tartrate | 699 | 155 |
| Tramadol Hcl | Tramadol Hcl | 571 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 543 | 124 |
| Simvastatin | Simvastatin | 539 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 529 | 117 |
| Metformin Hcl | Metformin Hcl | 508 | 140 |
| Hydrochlorothiazide | Hydrochlorothiazide | 476 | 124 |
| Allopurinol | Allopurinol | 413 | 107 |
| Sertraline Hcl | Sertraline Hcl | 371 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 356 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 331 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 322 | 90 |
| Warfarin Sodium | Warfarin Sodium | 309 | 58 |
| Jardiance | Empagliflozin | 301 | 41 |
| Glimepiride | Glimepiride | 290 | 81 |
| Memantine Hcl | Memantine Hcl | 290 | 44 |
| Carvedilol | Carvedilol | 275 | 61 |
| Trazodone Hcl | Trazodone Hcl | 273 | 57 |
| Donepezil Hcl | Donepezil Hcl | 270 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 268 | 91 |
| Pravastatin Sodium | Pravastatin Sodium | 262 | 63 |
| Metformin Hcl Er | Metformin Hcl | 249 | 54 |
| Spironolactone | Spironolactone | 248 | 54 |
| Montelukast Sodium | Montelukast Sodium | 237 | 49 |
| Lorazepam | Lorazepam | 235 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 216 | 49 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 210 | 42 |
| Famotidine | Famotidine | 206 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 193 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 191 | 43 |
| Enalapril Maleate | Enalapril Maleate | 186 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 183 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 174 | 43 |
| Buspirone Hcl | Buspirone Hcl | 169 | 24 |
| Meloxicam | Meloxicam | 168 | 53 |
| Lovastatin | Lovastatin | 161 | 38 |
| Mirtazapine | Mirtazapine | 149 | 37 |
| Prednisone | Prednisone | 149 | 80 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 147 | 33 |
| Bumetanide | Bumetanide | 140 | 32 |
| Clonazepam | Clonazepam | 140 | 31 |
| Fentanyl | Fentanyl | 135 | 12 |
| Myrbetriq | Mirabegron | 135 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 135 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 132 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | 27 |
| Amoxicillin | Amoxicillin | 120 | 78 |
| Azithromycin | Azithromycin | 119 | 81 |
| Celecoxib | Celecoxib | 118 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 117 | 62 |
| Finasteride | Finasteride | 116 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 51 |
| Oxybutynin Chloride | Oxybutynin Chloride | 112 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 112 | 13 |
| Cefdinir | Cefdinir | 111 | 71 |
| Torsemide | Torsemide | 111 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 109 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 27 |
| Atenolol | Atenolol | 101 | 23 |
| Ozempic | Semaglutide | 101 | 16 |
| Farxiga | Dapagliflozin Propanediol | 100 | 12 |
| Januvia | Sitagliptin Phosphate | 99 | 11 |
| Nystatin | Nystatin | 98 | 42 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 96 | 66 |
| Ondansetron Hcl | Ondansetron Hcl | 96 | 51 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 95 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 94 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 94 | 31 |
| Pregabalin | Pregabalin | 91 | 16 |
| Linzess | Linaclotide | 90 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 86 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | 14 |
| Alprazolam | Alprazolam | 83 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 81 | 15 |
| Digoxin | Digoxin | 81 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 17 |
| Lamotrigine | Lamotrigine | 78 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 75 | 15 |
| Cephalexin | Cephalexin | 74 | 45 |
| Baclofen | Baclofen | 73 | 12 |
| Levetiracetam | Levetiracetam | 73 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 13 |
| Latanoprost | Latanoprost | 71 | 15 |
| Verapamil Er | Verapamil Hcl | 71 | 17 |
| Xarelto | Rivaroxaban | 71 | 13 |
| Terazosin Hcl | Terazosin Hcl | 68 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 67 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 20 |
| Trulicity | Dulaglutide | 66 | suppressed |
| Ezetimibe | Ezetimibe | 63 | 16 |
| Novolog Flexpen | Insulin Aspart | 63 | 18 |
| Clonidine Hcl | Clonidine Hcl | 62 | 22 |
| Bupropion Xl | Bupropion Hcl | 61 | suppressed |
| Synthroid | Levothyroxine Sodium | 61 | 15 |
| Fluconazole | Fluconazole | 60 | 33 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 58 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 58 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 57 | 16 |
| Loperamide | Loperamide Hcl | 57 | 37 |
| Metolazone | Metolazone | 56 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 12 |
| Aripiprazole | Aripiprazole | 54 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | 17 |
| Benazepril Hcl | Benazepril Hcl | 53 | 16 |
| Mounjaro | Tirzepatide | 52 | 12 |
| Levofloxacin | Levofloxacin | 51 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 11 |
| Clozapine | Clozapine | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 49 | 18 |
| Diclofenac Potassium | Diclofenac Potassium | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 14 |
| Diazepam | Diazepam | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 24 |
| Gemfibrozil | Gemfibrozil | 45 | 11 |
| Alendronate Sodium | Alendronate Sodium | 44 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 21 |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 39 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 41 | 13 |
| Valacyclovir | Valacyclovir Hcl | 41 | 21 |
| Propranolol Hcl Er | Propranolol Hcl | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 40 | 13 |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 39 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 39 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Metronidazole | Metronidazole | 38 | 20 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 38 | 13 |
| Chlorthalidone | Chlorthalidone | 37 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 37 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 36 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 28 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Amantadine | Amantadine Hcl | 31 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 12 |
| Acetazolamide | Acetazolamide | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 12 |
| Valsartan | Valsartan | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 17 |
| Buprenorphine Hcl | Buprenorphine Hcl | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 14 |
| Risperdal Consta | Risperidone Microspheres | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 24 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 18 |
| Ondansetron Odt | Ondansetron | 24 | 22 |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 22 | 22 |
| Budesonide | Budesonide | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Restasis | Cyclosporine | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Xifaxan | Rifaximin | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Multaq | Dronedarone Hcl | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Cefprozil | Cefprozil | 17 | 11 |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Lyrica | Pregabalin | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Ofloxacin | Ofloxacin | 17 | 16 |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Savella | Milnacipran Hcl | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Fanapt | Iloperidone | 12 | suppressed |
| Felbamate | Felbamate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | 12 |
| Niacin Er | Niacin | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Rufinamide | Rufinamide | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,004.52 · 66 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, ENFLONSIA, FANAPT, GARDASIL 9, GEMTESA, HETLIOZ, IBSRELA, Kerendia, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, PROQUAD, QULIPTA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VAXELIS, VAXNEUVANCE, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Fanapt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error